Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Rhea-AI Summary

Cybin, a clinical-stage biopharmaceutical company, announced that CEO Doug Drysdale will participate in a virtual fireside chat at the Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The presentation will be webcast live at 12:40 p.m. ET and will later be available on Cybin’s investor relations website. The company is focused on developing innovative psychedelic treatments for mental healthcare.

Positive

• Cybin's CEO Doug Drysdale's participation in the Alliance Global Partners Healthcare Company Showcase boosts visibility and investor engagement.
• The webcast of the event could attract potential investors and stakeholders, enhancing market interest in Cybin.
• Cybin continues to position itself as a leader in developing next-generation psychedelic treatments for mental healthcare.

Negative

• No new financial or clinical trial data provided, which may not satisfy investors looking for concrete updates.
• The announcement lacks details on progress or milestones in Cybin's development pipeline, leading to potential investor uncertainty.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024.

Mr. Drysdale’s presentation will be webcast live on Tuesday, May 21, 2024, at 12:40 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514524687/en/

Investors & Media:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

When will Cybin's CEO participate in the Alliance Global Partners Healthcare Company Showcase?

Doug Drysdale will participate in the showcase on May 21, 2024.

What time will Cybin's fireside chat be webcast?

The fireside chat will be webcast live at 12:40 p.m. ET on May 21, 2024.

Where can I access the archived webcast of Cybin's presentation?

The archived webcast will be available on Cybin's investor relations website on the Events & Presentations page.

What is Cybin's stock symbol?

Cybin's stock symbols are CYBN on the NYSE American and Cboe CA.

What is the focus of Cybin's business?

Cybin is focused on developing new and innovative next-generation psychedelic treatment options for mental healthcare.